Eloxx Pharmaceuticals, Inc.

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing RNA-modulating medicines for rare and ultra-rare genetic disorders caused by nonsense mutations. The company’s work centers on small-molecule product candidates designed to encourage ribosomal readthrough of premature stop codons, with the goal of helping restore production of full-length proteins. Its current pipeline includes exaluren, which is being developed for rare kidney diseases, and licensed programs such as ZKN-013 for rare skin diseases. Eloxx Pharmaceuticals concentrates on precision medicine approaches for patients with conditions that have limited treatment options, positioning the company within the specialized rare-disease segment of biotechnology. Headquartered in Arlington, Massachusetts, Eloxx Pharmaceuticals is a focused research-driven company operating at the intersection of molecular biology, drug development, and orphan disease therapeutics.